XML 132 R69.htm IDEA: XBRL DOCUMENT
v3.25.1

Share capital - Disclosure of Detail of Share Capital Transactions (Details) - EUR (€) |  |  |  |  |  |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 22, 2024 | Dec. 31, 2023 | Dec. 29, 2023 | Dec. 13, 2023 | Nov. 10, 2023 | Nov. 07, 2023 | Sep. 11, 2023 | Jun. 27, 2023 | Apr. 20, 2023 | Mar. 11, 2022 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Equity at beginning of period |  |  |  |  |  |  |  |  |  |  | € (1,843,000) | € (27,045,000) | € 26,790,000
Capital increase |  |  |  |  |  |  |  |  |  |  | 0 | 61,641,000 | 0
Free shares attribution |  |  |  |  |  |  |  |  |  |  |  |  | 0
Equity at end of period |  | € (1,843,000) |  |  |  |  |  |  |  |  | (65,704,000) | (1,843,000) | (27,045,000)
Janssen | Tranche two |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase transaction costs |  |  | € (79,000) |  |  |  |  |  |  |  |  |  |
Janssen | Tranche three |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase transaction costs |  |  | € (813,000) |  |  |  |  |  |  |  |  |  |
AGA 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  |  |  |  |  | € 8,805.69 |  |  |
Share Capital |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Equity at beginning of period | € 1,413,999.85 |  |  |  |  |  |  |  | € 1,046,276.16 |  | 1,413,999.85 | 1,046,000 | 1,045,000
Capital increase |  |  |  |  |  |  |  |  |  |  | 9,000 | 368,000 | 2,000
Equity at end of period | 1,422,805.53 | € 1,413,999.85 |  |  |  |  |  |  | 1,056,911.46 |  | € 1,422,805.53 | € 1,413,999.85 | € 1,046,000
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares outstanding at beginning of period (in shares) |  |  |  |  |  |  |  |  |  |  | 47,133,328 | 34,875,872 | 34,825,872
Capital increase, net (in shares) |  | 12,257,456 |  |  |  |  |  |  |  |  | 293,523 | 12,257,456 | 50,000
Number of shares outstanding at end of period (in shares) |  | 47,133,328 |  |  |  |  |  |  |  |  | 47,426,851 | 47,133,328 | 34,875,872
Share Capital | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  | € 113,000 |  | € 29,000 |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) |  |  |  |  | 3,762,923 |  | 959,637 |  |  |  |  |  |
Share Capital | Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  | € 75,000 |  |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) |  |  |  |  |  | 2,492,223 |  |  |  |  |  |  |
Share Capital | ADS Shares |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  | € 114,000 |  |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) |  |  |  |  |  | 3,786,907 |  |  |  |  |  |  |
Share Capital | ADS Shares | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  | € 27,000 |  |  |  |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) |  |  |  | 901,256 |  |  |  |  |  |  |  |  |
Share Capital | AGA 2021 |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  |  |  |  | € 11,000 |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) |  |  |  |  |  |  |  |  | 354,510 |  |  |  |
Share Capital | AGA 2022 |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase | € 9,000 |  |  |  |  |  |  |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase, net (in shares) | 293,523 |  |  |  |  |  |  |  |  |  |  |  |
Premiums related to share capital |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Equity at beginning of period |  |  |  |  |  |  |  |  |  |  | € 312,742,000 | € 255,760,000 | € 255,767,000
Capital increase |  |  |  |  |  |  |  |  |  |  | 1,000 | 56,982,000 |
Prior period adjustments |  | € 1,000 |  |  |  |  |  |  |  |  | 1,000 |  |
Free shares attribution |  |  |  |  |  |  |  |  |  |  |  |  | (7,000)
Equity at end of period |  | € 312,742,000 |  |  |  |  |  |  |  |  | € 312,743,000 | € 312,742,000 | € 255,760,000
Premiums related to share capital | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  | € 18,965,000 |  | € 4,642,000 |  |  |  |  |  |
Premiums related to share capital | Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  | € 12,561,000 |  |  |  |  |  |  |
Capital increase transaction costs |  |  |  |  |  | (758,000) |  |  |  |  |  |  |
Premiums related to share capital | ADS Shares |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  |  |  | 19,086,000 |  |  |  |  |  |  |
Capital increase transaction costs |  |  |  |  |  | € (1,140,000) |  |  |  |  |  |  |
Premiums related to share capital | ADS Shares | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase |  |  |  | € 4,542,000 |  |  |  |  |  |  |  |  |
Premiums related to share capital | AGA 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |  |
Free shares attribution |  |  |  |  |  |  |  | € (26,000) |  |  |  |  |

X
- Definition The amount of residual interest in the assets of the entity after deducting all its liabilities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2024-01-01 -Paragraph 24 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2024-01-01 -Paragraph 32 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2024-01-01 -Paragraph 93 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2024-01-01 -Paragraph 93 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard -URIDate 2024-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2024-01-01 -Paragraph 93 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard -URIDate 2024-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard -URIDate 2024-03-27 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_Equity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | ifrs-full_EquityAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase in equity through the issue of equity instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_IssueOfEquity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares issued by the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfSharesIssued
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 79 -Subparagraph a -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfSharesOutstanding
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) From Prior Period Adjustments + References No definition available. + Details
Name: | nbx_IncreaseDecreaseFromPriorPeriodAdjustments
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) Through Attribution Of Free Shares, Equity + References No definition available. + Details
Name: | nbx_IncreaseDecreaseThroughAttributionOfFreeSharesEquity
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Shares Issued, Issuance Cost + References No definition available. + Details
Name: | nbx_SharesIssuedIssuanceCost
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=nbx_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=nbx_ADSSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |